Area riservata



 




Dislipidemia PPARs e sindome metabolica
Scritto da Stagnaro Sergio   
Indice
Inizio
Fattori di rischio
PPARs: sottotipi
Conclusione e Bibliografia
Bibliografia 2
Bibliografia 3 e Commenti
Articolo completo

10) Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.

11) Kaplan NM: The deadly quartet. Upper-body obesity, glucose intolerance,
hypertriglyceridemia, and hypertension. Arch Intern Med 1989, 149:1514-1520.

14) Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.

15) Hayden MR, Tyagi SC: Intimal redox stress: Accelerated atherosclerosis in
metabolic syndrome and type 2 diabetes mellitus. Atheroscleropathy. Cardiovasc Diabetol 2002, 1:3.

16) National Heart, Lung, and Blood Institute: Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Bethesda, Md: National Cholesterol Education Program (NCEP), National Institutes of Health; 2001. Available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3_rpt.htm

17) Auwerx J: PPARgamma, the ultimate thrifty gene. Diabetologia 1999, 42:1033-1049.

18) Porte D Jr, Kahn SE: Beta- cell dysfunction and failure in type 2 diabetes:
potential mechanisms. Diabetes 2001, 50 Suppl 1:S160-S163.

19) Guerre-Millo M, Rouault C, Poulain P, Andre J, Poitout V, Peters JM, Gonzalez FJ,
Fruchart JC, Reach G, Staels B: PPAR-alpha-null mice are protected from high-fat
diet-induced insulin resistance. Diabetes 2001, 50:2809-2814

20) Berger J, Moller DE: The mechanisms of action of PPARs. Annu Rev Med 2002,
53:409-435.

21) Vosper H, Khoudoli G, Graham T, Palmer C: Peroxisome proliferator-activated
receptor agonists, hyperlipidaemia, and atherosclerosis. Pharmacol Ther 2002, 95:47-62

22) Groop LC: Insulin resistance: the fundamental trigger of type 2 diabetes. Diab
Obes Metab 1999;1 Suppl 1:S1-7 .

23) Knowler WC, Barrett-Connor E, Fowler SE et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403

24) . Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, et al: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997, 20:537-544

25) Stagnaro S., Diet and Risk of Type 2 Diabetes. N Engl J Med. 2002 Jan 24;346(4):297-298. letter [MEDLINE].

26) Stagnaro-Neri M., Stagnaro S., Semeiotica Biofisica: la manovra di Ferrero-Marigo nella diagnosi clinica della iperinsulinemia-insulino resistenza. Acta Med. Medit. 13, 125, 1997.


 

Per inserire un commento è necessario essere registrati